Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery

What Was Tested

This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).

The purpose of this article is to analyze the incidence of the postoperative vasoplegic syndrome, to consider its prognosis, and to evaluate the effect of intravenous methylene blue on mortality.

Why It Was Studied

The discovery of nitric oxide as mediator in cardiac postoperative vasoplegia encourages the use of inhibitory drugs such as methylene blue.

This drug has been used with favorable results in isolated cases.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

Cardiac surgery patients were consecutively included.

Vasoplegic syndrome was defined by the presence of the following five criteria: (1) hypotension, (2) low filling pressures, (3) high or normal cardiac index, (4) low peripheral resistance, and (5) vasopressor requirements.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Methylene blue (non-peptide stack partner) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some participants received a placebo instead of Methylene blue (non-peptide stack partner), giving a reference point.

What Was Measured

PubMed files the paper under topics including Cardiopulmonary Bypass, Cause of Death, Coronary Disease, Enzyme Inhibitors, Heart Valve Diseases, Hemodynamics and Hypotension.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Methylene blue (non-peptide stack partner).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2004 (The Annals of thoracic surgery), a journal based in Netherlands.

More context: the Methylene blue (non-peptide stack partner) compound page.